Krishna Institute of Medical Sciences approves Q2 financials and key reappointments
Krishna Institute of Medical Sciences · Healthcare Services
Key highlights
- Approved unaudited standalone and consolidated financial results for Q2 and H1 ended 30 Sept 2026 with limited review reports
- Approved merger of wholly-owned subsidiary KIMS Hospitals Private Limited with Krishna Institute of Medical Sciences Limited
- Reappointed Dr. Abhinay Bollineni as Director & CEO, Dr. Bhaskara Rao Bollineni as Chairman & Managing Director, and Ms. Dandamudi Anitha as Whole-time Director for 5-year terms
Why it's rated notable: The filing approves the quarter results but states no net profit or revenue figures, so no year-on-year change can be computed, and the merger carries no stated value and remains subject to further approvals, which keeps the level at medium.
Original filing
Board Meeting Outcome for Outcome Of Board Meeting Held On 04Th November 2026 Pursuant To Regulation 30 And 33 Of SEBI (LODR) Regulations, 2015.
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Krishna Institute of Medical Sciences
- Financial resultsNotableKrishna Institute of Medical Sciences Ltd announces Q2 results and key appointments
- Acquisition / mergerNotableKIMS announces acquisition of up to 51% stake in Insignia Healthcare Pvt Ltd
Other acquisition / merger filings this fortnight
- Sahasra Electronic Solutions receives NSE No Objection Letter for scheme of amalgamation
- Narayana Hrudayalaya: NCLT sanctions demerger of NH Integrated Care clinics into company
- TPL Plastech Ltd reports Q2 & H1 FY27 unaudited results; Q2 PAT ₹83.8 Mn, up 22.3% YoY
- Websol Energy approves Sept 2026 quarter results and 40% stake in Bright Earth Cell
- Aurobindo Pharma reports unaudited Q2 and half-year results ended September 30, 2026
- Gretex Industries board approves unaudited half-year results to Sept 30, 2026
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.